Normative database for OCT device cleared by FDA

Article

The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).

The FDA has cleared an age-adjusted retinal nerve fibre layer thickness normative database for a proprietary ocular coherence tomography (OCT) device, Spectralis (Heidelberg Engineering).

This new tool has been designed to enable the assessment of glaucoma risk from a patient’s first office visit. Additionally, in combination with proprietary fovea-to-disc alignment software and new posterior pole asymmetry analysis the database aims to increase the power of the OCT instrument for glaucoma risk assessment and progression management.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.